Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes (SANDIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03885245
Recruitment Status : Not yet recruiting
First Posted : March 21, 2019
Last Update Posted : March 21, 2019
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
Patients with obese late onset (after childhood) asthma can have lower FeNO levels, yet be highly symptomatic and poorly responsive to inhaled steroids. This is a common asthma phenotype, particularly among females. This reduction of NO occurs through increased arginase activity and uncoupling of NO synthase (NOS), by accumulation of asymmetric di-methyl arginine (ADMA), which further lowers the L-arginine/ADMA ratio, preferentially promoting reactive oxygen species (ROS) formation and inflammation at the expense of NO. Indeed, in patients with obese late onset asthma, lower L-arginine/ADMA plasma ratios are associated with reduced FeNO, increased bronchial hyperreactivity, and greater asthma morbidity. In our pilot studies, the administration of L-citrulline, as an L-arginine donor, to patients with obese late onset asthma increased the L-arginine/ADMA ratio, FeNO levels, and improved asthma control and lung function. Therefore, the objectives of the protocol are to: a) determine the efficacy of L-citrulline, as an add-on treatment to improve the asthma control and lung function in obese late onset asthmatics; b) leverage the use of asthmatic and control cells to further understand obesity-related changes in epithelial airway NO metabolism, and how these changes relate to bronchoconstriction and lung function, c) determine airway epithelial changes in mitochondrial function and bioenergetics in obese late onset asthmatics and how these are modified by L-citrulline. To do this, 54 obese late onset asthmatics with suboptimal control will be blindly randomized, in a cross over study, comparing 15g/day of L-citrulline vs. placebo, in two 8-week treatment periods with a 6-week washout in between. The co-primary study outcomes are asthma control (ACQ, ACT) and FeNO, and secondary endpoints plasma L-arginine/ADMA, FEV1 and PC20 methacholine. Parallel to this study, a small study of 10 healthy obese controls will receive open label L-citrulline for 8 weeks to establish comparative reference values for the study aims. During the initial treatment phase, 50% of study participants will be randomly allocated to undergo pre and post L-citrulline treatment bronchoscopy to obtain BAL and airway epithelial cells. The research group proposing this study is highly experience in asthma clinical trials, implementation of cross over design studies, and in the use of research bronchoscopies.

Condition or disease Intervention/treatment Phase
Asthma Obesity Drug: L-ctirulline Drug: Matching Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes to Increase Airway L-arginine/ADMA Ratio and Improve Asthma Control
Estimated Study Start Date : August 1, 2019
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : July 1, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: L-citrulline
L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 8 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 6 weeks and then enter crossover phase of an additional 8 weeks. Drug will be dispensed at Visit 4.
Drug: L-ctirulline
8 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
Other Name: L-citrulline

Placebo Comparator: Matching Placebo
Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 8 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 6 weeks and then enter crossover phase of an additional 8 weeks. Drug will be dispensed at Visit 4.
Drug: Matching Placebo
8 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)




Primary Outcome Measures :
  1. Change in Asthma Control Questionnaire [ Time Frame: Through study completion, up to 32 weeks ]
    to determine L-citrulline efficacy, reduction in questionnaire scores determined by administering the questionnaires before, mid-way, and after during each treatment phase to see if there's a change in scores.

  2. Change in Asthma Control Test [ Time Frame: Through study completion, up to 32 weeks ]
    To determine L-citrulline efficacy, reduction in questionnaires scores determined by administering the questionnaires before, mid-way, and after during each treatment phase to see if there's a change in scores.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Adequate completion of informed consent process
  2. Male and female patients
  3. Physician diagnosis of asthma
  4. Able to perform reproducible spirometry according to ATS criteria
  5. Pre-bronchodilator FEV1 >/= 50% of predicted at Visit 0
  6. Confirmation of asthma
  7. All racial/ethnic backgrounds may participate.
  8. BMI >/= 30
  9. Regular treatment with ICS or ICS/LABA or LAMA combination medication for at least 1 month; participants can be on biologics.
  10. Smoking history </= 10 pack years and no smoking in the last 3 months
  11. Age of asthma onset (diagnosis) >/= 12 years
  12. FeNO </= 30 ppb
  13. ACQ >/= 0.50 or ACT </=19

Exclusion Criteria:

  1. Respiratory tract infection within the 4 weeks prior to Visit 1
  2. Oral or systemic corticosteroid burst (for any indication) within the 4 weeks prior to Visit 0. (One-time doses, such as intra-articular injections into a shoulder or knee joint, require a 4-week washout prior to Visit 0)
  3. Asthma-related ER visit within the previous 4 weeks of Visit 0
  4. History of ICU admission/intubation due to asthma in the past 1 year
  5. 3 or more asthma exacerbations requiring treatment with systemic corticosteroids for more than three days in the past year consistent with severe asthma
  6. Asthma exacerbation requiring systemic corticosteroids within the 4 weeks prior to Visit 0.
  7. Chronic renal failure
  8. Positive urine cotinine or THC test on the day of the bronchoscopy visit
  9. Positive urine (or serum) pregnancy test at Visit 0 or at any time during the study
  10. Intolerance or allergy to L-arginine or L-citrulline
  11. Concomitant use of PDE5 drugs or oral mononitrates
  12. Untreated sleep apnea
  13. Participant in an interventional drug study or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03885245


Contacts
Layout table for location contacts
Contact: Asthma Research 1 (844) 365-0852 asthmaresearch@ucdenver.edu

Sponsors and Collaborators
University of Colorado, Denver
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Fernando Holguin, MD, MPH University of Colorado Denver- Anschutz Medical Campus

Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT03885245     History of Changes
Other Study ID Numbers: 19-0219
First Posted: March 21, 2019    Key Record Dates
Last Update Posted: March 21, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Lung Diseases, Obstructive
Lung Diseases
Overweight
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Body Weight
Signs and Symptoms